Study of the Evolution of the Expression of the LAMP-2 Protein During the Advance in Age

Aging Clinical Trial

Official title:

Study of the Evolution of the Expression of the LAMP-2 Protein During the Advance as Well as Variations and Allelic Mutations in the Main Genes Involved in the Occurrence of Age-related Myelodysplastic Syndromes

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06357923
• Other study ID #: 23-PP-13
• Secondary ID: 2024-A00321-46
• Status: Not yet recruiting
• Phase: N/A
• Start date: May 1, 2024
• Est. completion date: May 1, 2026

Study information

• Verified date: April 2024
• Source: Centre Hospitalier Universitaire de Nice
• Contact: Andrea CICCONE
• Phone: 0492034702
• Email: ciccone.a[@]hu-nice.fr
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Recruitment on the RAV pole in consultation or day hospital. Competitive recruitment of subjects > 60 years of age respecting a male/female ratio = 1.

Description:

Recruitment on the RAV pole in consultation or day hospital. Competitive recruitment of subjects > 60 years of age respecting a male/female ratio = 1. After explanations and collection consent, collection of the patient's socio-demographic and medical characteristics and then carrying out a Peripheral venous blood sample (2 x 5ml tubes).

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 100
• Est. completion date: May 1, 2026
• Est. primary completion date: May 2, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 60 Years to 99 Years

Eligibility

Inclusion Criteria:

• Men and women over 60 years of age.

Exclusion Criteria:

• Inability to Understand Consent,

• Non-Security Beneficiaries

• social, subjects protected by law, subjects deprived of liberty,

• history of breast cancer,

• brain tumor,

• melanoma,

• colon cancer,

• lung cancer,

• prostate cancer,

• lymphoma,

• myeloma,

• syndrome myelodysplastic/myeloproliferative,

• leukemia,

• history of radiation therapy.

Related Conditions & MeSH terms

• Aging

Intervention

Diagnostic Test:
• dosage
Presence of mutation on the gene panel and Frequency of allele variation

Locations

Country	Name	City	State
France	Chu de Nice	Nice

Sponsors (1)

Lead Sponsor	Collaborator
Centre Hospitalier Universitaire de Nice

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Expression level of LAMP2 (protein and isoform A and B mRNA)	dosage	day 0
Secondary	Presence of mutation in the "Oncomin Myeloid Reasearch Assay" gene panel targeting approximately 40 Different genes	dosage	day 0